Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Rochelle M. Gellatly, Cia Connell, Christianne Tan, Nick Andrianopoulos, Andrew E. Ajani, David J. Clark, Shane Nanayakkara, Martin Sebastian, Angela Brennan, Melanie Freeman, Jessica O’Brien, Laura A. Selkrig, Christopher M. Reid, Stephen J. Duffy

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Background: Glycoprotein IIb/IIIa inhibitors (GPIs) are a treatment option in the management of acute coronary syndromes (ACSs). Evidence supporting the use of GPIs predates trials establishing the benefits of P2Y12 inhibitors, routine early invasive therapy, and thrombectomy devices in patients with ACS. Objective: The aim of this study was to determine trends in GPI use and their associated outcomes in contemporary practice. Methods: We assessed GPI use in patients with ACS undergoing percutaneous coronary intervention (PCI) from the Melbourne Interventional Group registry (2005-2013). The primary endpoint was the 30-day incidence of major adverse cardiovascular events (MACE). The safety endpoint was in-hospital major bleeding. Results: GPIs were used in 40.5% of 12 357 patients with ACS undergoing PCI. GPI use decreased over the study period (P for trend <0.0001). Patients were more likely to receive GPIs if they were younger, presented with a ST-elevation myocardial infarction (STEMI), had more complex (B2/C-type) lesions, and when thrombectomy devices were used (all P < 0.0001). MACE were higher in patients receiving GPI (4.9% vs 4.1%, P = 0.03). Propensity score matching revealed no difference in 30-day mortality and 30-day MACE (odds ratio [OR] = 1.00; 95% CI = 0.99-1.004 and OR = 1.01; 95% CI = 0.99-1.02, respectively). GPI use was associated with more bleeding complications (3.6% vs 1.8%, P < 0.0001). Conclusion and Relevance: GPI use in ACS patients undergoing PCI has declined, and use appears to be dictated by ACS type and lesion complexity, as opposed to high-risk comorbidities. GPI use was associated with a doubling in bleeding complications.

Original languageEnglish
Pages (from-to)414-422
Number of pages9
JournalAnnals of Pharmacotherapy
Volume54
Issue number5
DOIs
Publication statusPublished - May 2020

Keywords

  • acute coronary syndrome
  • bleeding
  • drugs
  • glycoprotein-IIb/IIIa inhibitors
  • percutaneous coronary intervention

Cite this